Unitat Atenció Crohn-Colitis, Hospital Universitari Vall d'Hebron, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Barcelona, Spain.
J Crohns Colitis. 2012 Oct;6(9):881-6. doi: 10.1016/j.crohns.2012.01.019. Epub 2012 Feb 14.
Inflammatory bowel disease impairs patients' health related quality of life (HRQOL). AntiTNFα agents control disease activity effectively. An ambitious goal of treatment is to achieve the normalization of health. This can be assessed by using a cut-off scoring threshold of the IBDQ-36 questionnaire. It has not been established if antiTNFα treatment is able to restore to normal patients' HRQOL.
To determine whether patients with Crohn's disease (CD) and ulcerative colitis (UC) in clinical remission after one year treatment with antiTNFα agents achieve normalization of their HRQOL.
Observational and cross-sectional study in patients treated with antiTNFα for one year and in sustained clinical remission. Patients completed the specific questionnaire IBDQ-36. Complete restoration of health was considered achieved when global score of IBDQ-36 was higher than 209 points.
54 patients (43 with CD and 11 with UC) were included. Thirty patients received adalimumab and 24 infliximab. Median global score of the IBDQ-36 was 231, without differences between CD and UC (228 vs 235 respectively, p=ns). Normalization of HRQOL was achieved in all 11 UC patients and in 29 out of 43 CD patients (67%). In our sample population, restoration of health was significantly more frequent in UC than in CD (p<0.05).
One-year clinical remission induced by antiTNFα treatment restores perception of health to normal in most patients with IBD.
炎症性肠病（IBD）会损害患者的健康相关生活质量（HRQOL）。抗 TNFα 药物可有效控制疾病活动。治疗的一个雄心勃勃的目标是实现健康的正常化。这可以通过使用 IBDQ-36 问卷的截断评分阈值来评估。尚未确定抗 TNFα 治疗是否能够使患者的 HRQOL 恢复正常。
确定经过一年抗 TNFα 治疗后处于临床缓解的克罗恩病（CD）和溃疡性结肠炎（UC）患者的 HRQOL 是否能够恢复正常。
对接受抗 TNFα 治疗一年且持续临床缓解的患者进行观察性和横断面研究。患者完成了特定的 IBDQ-36 问卷。当 IBDQ-36 的总分为 209 分以上时，认为完全恢复健康。
共纳入 54 例患者（43 例 CD 和 11 例 UC）。30 例患者接受阿达木单抗治疗，24 例患者接受英夫利昔单抗治疗。IBDQ-36 的中位总分是 231，CD 和 UC 之间没有差异（分别为 228 和 235，p=ns）。11 例 UC 患者和 43 例 CD 患者中的 29 例（67%）达到了 HRQOL 的正常化。在我们的样本人群中，UC 患者的健康恢复明显比 CD 患者更频繁（p<0.05）。
抗 TNFα 治疗诱导的一年临床缓解可使大多数 IBD 患者对健康的感知恢复正常。
